Current Report Filing (8-k)
June 08 2023 - 3:07PM
Edgar (US Regulatory)
0001359931
false
0001359931
2023-06-07
2023-06-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 7, 2023
Protara Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-36694 |
|
20-4580525 |
(State or other jurisdiction
of incorporation) |
|
(Commission File No.) |
|
(IRS Employer
Identification No.) |
345 Park Avenue South
Third Floor
New York, NY |
|
10010 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (646) 844-0337
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading Symbol(s) |
|
Name of each
exchange on which registered |
Common Stock, par value $0.001 per share |
|
TARA |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security
Holders.
The Annual Meeting of Stockholders (the “Annual
Meeting”) of Protara Therapeutics, Inc. (the “Company”) was held on June 7, 2023. As of April 11, 2023, the record date
for the Annual Meeting, there were 11,307,962 shares of the Company’s common stock outstanding and entitled to vote. A summary
of the matters voted upon at the Annual Meeting and the final voting results are set forth below.
Proposal 1. Election of Directors.
The Company’s stockholders elected the three
persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2026 Annual
Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results were as follows:
| |
Votes For | | |
Votes
Withheld | | |
Broker
Non-Votes | |
Jesse Shefferman | |
| 5,677,709 | | |
| 252,982 | | |
| 2,255,211 | |
Barry Flannelly, Pharm. D. | |
| 5,625,929 | | |
| 304,762 | | |
| 2,255,211 | |
Cynthia Smith | |
| 5,663,928 | | |
| 266,763 | | |
| 2,255,211 | |
Proposal 2. Ratification of the Selection
of Independent Registered Public Accounting Firm.
The Company’s stockholders ratified the
selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2023. The final voting results were as follows:
Votes For |
|
Votes Against |
|
Abstentions |
8,155,867 |
|
29,326 |
|
709 |
Proposal 3. Approval, on an Advisory Basis,
of the Compensation of the Company’s Named Executive Officers.
The Company’s stockholders approved, on
an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy
statement for the Annual Meeting. The final voting results were as follows:
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
5,571,777 |
|
296,338 |
|
62,576 |
|
2,255,211 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protara Therapeutics, Inc. |
|
|
|
Dated: June 8, 2023 |
By: |
/s/ Patrick Fabbio |
|
|
Patrick Fabbio |
|
|
Chief Financial Officer |
2
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Oct 2023 to Oct 2024